Drug Type Antibody drug conjugate (ADC), Biosimilar |
Synonyms Fam-trastuzumab deruxtecan-NXKI Biosimilar (EirGenix, Inc.), EG12170 |
Target |
Action antagonists, inhibitors |
Mechanism HER2 antagonists(Receptor tyrosine-protein kinase erbB-2 antagonists), TOP1 inhibitors(DNA topoisomerase I inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |



| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D11529 | Trastuzumab-deruxtecan biosimilar(EirGenix) |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| HER2 Positive Breast Cancer | Preclinical | China | 01 Aug 2026 |






